Philadelphia, Pennsylvania, August 3, 2026
Signant Health announced the launch of Forecasting & Planning Assist™, a purpose-built agentic AI capability for clinical supply forecasting and planning designed to help clinical supply experts analyze data, execute configuration tasks, and identify supply and enrollment risks across clinical trial portfolios. Integrated into Signant Health’s existing clinical supply Forecasting & Planning solution, the technology enables users to interact with clinical supply data through plain-language prompts, while maintaining expert oversight and control. The launch expands the application of artificial intelligence within regulated clinical trial operations and is intended to reduce routine administrative workloads so clinical supply professionals can dedicate more time to complex, high-impact supply decisions.
Four AI Agents Automate Clinical Supply Planning Workflows
Forecasting & Planning Assist™ includes four purpose-built AI agents licensed together as an integrated bundle, with each agent addressing specific clinical supply activities. The Admin Agent enables users to query and manage trial data and system administration, while the Trial Health Agent monitors clinical trial portfolios for enrollment data gaps and trial health risks. The Demand Planning Agent supports updates to enrollment actuals and modeling of patient recruitment scenarios, and the Supply Planning Agent identifies potential supply risks involving lots, depots and studies before they escalate. Together, the agents are designed to give clinical supply experts faster access to operational information and enable defined actions directly within established workflows. Signant Health said the technology can help teams query data, execute configuration activities, and monitor supply and enrollment risks across their portfolios within seconds. This approach is intended to address the increasing volume of routine operational work generated as clinical trial portfolios become larger and more complex, while allowing experienced supply professionals to retain responsibility for important decisions.
GxP-Compliant Audit Trails Support Regulated AI Operations
A key feature of the new capability is its focus on operating within a regulated clinical trial environment. According to Signant Health, every AI agent operates within each user’s existing role-based permissions and maintains a full GxP-compliant audit trail throughout its activities. The agents have been trained specifically on clinical supply workflows and function within the systems users already know, meaning organizations do not need to introduce a separate interface for the technology. Signant Health also states that no additional governance is required for use of the integrated agents. The company emphasizes that clinical supply experts remain in control while the AI performs activities such as information retrieval, monitoring and execution of defined tasks. This combination of agentic AI, human oversight, role-based access and GxP-compliant auditability is designed to make the technology suitable for regulated clinical supply operations, where traceability, accountability and control are important requirements.
Advertisement
Signant Health Expands AI Across Clinical Trial Supply Management
Forecasting & Planning Assist™ builds on Signant Health’s existing clinical supply Forecasting & Planning platform, which is designed to help clinical trial sponsors manage complex global supply portfolios while reducing costs, medication waste and emergency shipments. By adding agentic AI capabilities, Signant aims to accelerate how clinical supply teams interact with the platform and increase the operational value of existing forecasting and planning workflows. Clinical supply management is a critical component of clinical development because sponsors must balance patient enrollment forecasts, investigational product availability, inventory levels, depot requirements and changing trial conditions while minimizing shortages and unnecessary waste. The ability to identify potential risks earlier may help teams make faster and better-informed supply decisions across global studies. Forecasting & Planning Assist™ is available now, extending Signant Health’s broader portfolio of eClinical technologies used across traditional, virtual and hybrid clinical trial models. The company’s solutions span electronic clinical outcome assessments, clinician ratings, cognitive testing, wearable digital health technologies, electronic data capture, eConsent, randomization and trial supply management, supply chain management and data quality analytics. Signant Health reports that more than 600 sponsors and contract research organizations, including all Top 20 pharmaceutical companies, have used its eClinical solutions. The launch of Forecasting & Planning Assist represents another step in the growing adoption of AI-powered technologies for regulated clinical trials, with a particular focus on improving clinical supply forecasting, risk monitoring and operational efficiency while preserving expert control and GxP-compliant traceability.
Source: Signant Health press release
